lndc-20240415

0001005286-24-000050.txt : 20240419 0001005286-24-000050.hdr.sgml : 20240419 20240419163445 ACCESSION NUMBER: 0001005286-24-000050 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240415 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240419 DATE AS OF CHANGE: 20240419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIFECORE BIOMEDICAL, INC. \DE\ CENTRAL INDEX KEY: 0001005286 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943025618 STATE OF INCORPORATION: DE FISCAL YEAR END: 0528 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27446 FILM NUMBER: 24858264 BUSINESS ADDRESS: STREET 1: 3515 LYMAN BOULEVARD CITY: CHASKA STATE: MN ZIP: 55318 BUSINESS PHONE: 9523684300 MAIL ADDRESS: STREET 1: 3515 LYMAN BOULEVARD CITY: CHASKA STATE: MN ZIP: 55318 FORMER COMPANY: FORMER CONFORMED NAME: LANDEC CORP \CA\ DATE OF NAME CHANGE: 19951222 8-K 1 lndc-20240415.htm 8-K lndc-20240415

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 15, 2024

LIFECORE BIOMEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

000-27446

94-3025618

(State or other jurisdiction of incorporation)

(Commission file number)

(IRS Employer Identification No.)


3515 Lyman Boulevard
Chaska,	Minnesota	55318
(Address of principal executive offices)		(Zip Code)

(952) 368-4300

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock	LFCR	The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On April 15, 2024, Lifecore Biomedical, Inc., a Delaware corporation (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the fiscal quarter ended February 25, 2024 (the “Q3 Form 10-Q”) and its continued delay in filing its Quarterly Report on Form 10-Q for the quarterly periods ended August 27, 2023 and November 29, 2023 (the “Q1 Form 10-Q” and “Q2 Form 10-Q,” respectively, and together with the Q3 Form 10-Q, the “Filings”) with the Securities and Exchange Commission (the “SEC”), the Company continues not to be in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), and that the Nasdaq Hearings Panel would consider the delinquency in the filing of the Q3 Form 10-Q in rendering its determination regarding the Company’s continued listing on Nasdaq Global Select Market.

The Notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Select Market. As previously disclosed, Nasdaq had pre viously granted the Company until February 12, 2024 to regain compliance with the Listing Rule, and, on February 13, 2024, the Company received the Staff Delisting Determination notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company’s securities from Nasdaq as a result of the Company not being in compliance with the Listing Rule. The Company appealed the Staff Delisting Determination, and, on April 16, 2024, the Company appeared for the hearing in which the Company requested a further stay of any suspension or delisting action to enable the Company to regain compliance with the Listing Rule. The Nasdaq Hearings Panel has not yet issued its decision, although the Company anticipates that a decision will be forthcoming.

The Company continues to work diligently to complete the Filings and intends to file the Filings as promptly as possible to regain compliance under the Listing Rule. However, there can be no assurance that such periodic reports will be filed before the expiration of any stay granted by Nasdaq, or that the Nasdaq Hearing Panel will grant the Company’s request for a further stay of any suspension or delisting action

Item 7.01 Regulation FD Disclosure.

A press release, dated April 19, 2024, disclosing the Company’s receipt of the Notice referenced above is attached hereto as Exhibit 99.1.

The information furnished in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are furnished as part of this report:

Exhibit No.

Description

99.1

Press Release of Lifecore Biomedical, Inc., dated April 19, 2024

104

Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K includes information that constitutes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements. These forward-looking statements are based on the Company’s current beliefs, assumptions and expectations regarding future events, which in turn are based on information currently available to the Company. By their nature, forward-looking statements address matters that are subject to risks and uncertainties. A variety of factors could cause actual events and results to differ materially from those expressed in or contemplated by the forward-looking statements. These factors include, without limitation, the Company’s ability to respond in a timely and satisfactory matter to the inquiries by Nasdaq, the Company’s ability to regain compliance with Listing Rule prior to the delisting or suspension, or at all, any determination of Nasdaq, and the risk that the completion and filing of the Filings will take longer than expected. For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company’s filings with the Securities and Exchange Commission, including the risk factors contained in its most recent Annual Report on Form 10-K and the Company’s other subsequent filings with the SEC. The Company undertakes no

obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable laws.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 19, 2024

LIFECORE BIOMEDICAL, INC.

By:

/s/ John D. Morberg

John D. Morberg

Executive Vice President and Chief Financial Officer

EX-99.1 2 lfcr-delinquencypr4x19.htm EX-99.1 Document

Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report

CHASKA, Minn., April 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that, on April 15, 2024, the Company received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the fiscal quarter ended February 25, 2024 (the “Q3 Form 10-Q”) and its continued delay in filing its Quarterly Report on Form 10-Q for the quarterly periods ended August 27, 2023 and November 29, 2023 (the “Q1 Form 10-Q” and “Q2 Form 10-Q,” respectively, and together with the Q3 Form 10-Q, the “Filings”) with the Securities and Exchange Commission (the “SEC”), the Company continues not to be in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), and that the Nasdaq Hearings Panel would consider the delinquency in the filing of the Q3 Form 10-Q in rendering its determination regarding the Company’s continued listing on Nasdaq Global Select Market.

The Notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Select Market. As previously disclosed, Nasdaq had previously granted the Company until February 12, 2024 to regain compliance with the Listing Rule, and, on February 13, 2024, the Company received the Staff Delisting Determination notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company’s securities from Nasdaq as a result of the Company not being in compliance with the Listing Rule. The Company appealed the Staff Delisting Determination, and, on April 16, 2024, the Company appeared for the hearing in which the Company requested a further stay of any suspension or delisting action to enable the Company to regain compliance with the Listing Rule. The Nasdaq Hearings Panel has not yet issued its decision, although the Company anticipates that a decision will be forthcoming.

This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

About Lifecore Biomedical

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the Company, visit Lifecore’s website at www.lifecore.com.

Important Cautions Regarding Forward-Looking Statements

This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors among others, as the Company’s ability to respond in a timely and satisfactory matter to the inquiries by Nasdaq, the Company’s ability to regain compliance with Listing Rule prior to the delisting or suspension, or at all, any determination of Nasdaq, and the risk that the completion and filing of the Filings will take longer than expected. For additional information about factors that could cause actual results to differ materially from those described in the forward-looking

statements, please refer to our filings with the Securities and Exchange Commission, including the risk factors contained in our most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K. Forward-looking statements represent management’s current expectations and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.

Lifecore Biomedical, Inc. Contact Information:

Jeff Sonnek

(646) 277-1263

jeff.sonnek@icrinc.com

EX-101.SCH 3 lndc-20240415.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lndc-20240415_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 lndc-20240415_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image_0.jpg begin 644 image_0.jpg MB5!.1PT*&@H -24A$4@ #+( +" 8 #15442 "7!(67, $SE M !,Y0%USO"5 S$E$051XG.W.L0V ! #L8S^F\,4D"(^R?WE[AX M #X6MH# ;$A[ @ UI#P M + A[0$ VI#T # AK0' M V)#V !O2'@ &!# MV@, !LB"1)DB1)DB1)DB1)DB1)DB1)DO1'+V93]9'.=V') , $E%3D2N0F"" end XML 8 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information Document	Mar. 20, 2024
Cover [Abstract]
Document Type	8-K
Document Period End Date	Apr. 15, 2024
Entity Registrant Name	LIFECORE BIOMEDICAL, INC.
Entity Central Index Key	0001005286
Entity Incorporation, State or Country Code	DE
Entity File Number	000-27446
Entity Tax Identification Number	94-3025618
Entity Address, Address Line One	3515 Lyman Boulevard
Entity Address, City or Town	Chaska,
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55318
City Area Code	952
Local Phone Number	368-4300
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	LFCR
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Amendment Flag	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Document and Entity Information Document Sheet http://landec.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports lndc-20240415.htm lndc-20240415.xsd lndc-20240415_lab.xml lndc-20240415_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "lndc-20240415.htm": { "nsprefix": "lndc", "nsuri": "http://landec.com/20240415", "dts": { "inline": { "local": [ "lndc-20240415.htm" ] }, "schema": { "local": [ "lndc-20240415.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "lndc-20240415_lab.xml" ] }, "presentationLink": { "local": [ "lndc-20240415_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://landec.com/role/DocumentandEntityInformationDocument", "longName": "0000001 - Document - Document and Entity Information Document", "shortName": "Document and Entity Information Document", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lndc-20240415.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lndc-20240415.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://landec.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001005286-24-000050-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001005286-24-000050-xbrl.zip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end XML 18 lndc-20240415_htm.xml IDEA: XBRL DOCUMENT 0001005286 2024-03-19 2024-03-20 false 0001005286 8-K 2024-04-15 LIFECORE BIOMEDICAL, INC. DE 000-27446 94-3025618 3515 Lyman Boulevard Chaska, MN 55318 952 368-4300 false false false false Common Stock LFCR NASDAQ false